Abstract
Urate oxidase is considered as an important therapeutic enzyme used to control hyperuricemia. In spite of widespread distribution in numerous (micro)organisms, active urate oxidase is absent in higher primates (humans and apes) due to gene mutations. Considering the therapeutic significance of urate oxidase, further understanding on the inactivation process of the enzyme during primate evolution is critical. This study, therefore, aims to express genetically modified human urate oxidase in the methylotrophic yeast Pichia pastoris. Accordingly, the genetically modified human urate oxidase was successfully expressed intracellularly and extracellularly under the control of an alcohol oxidase promoter and was subjected to the enzyme activity assay. The results demonstrated that reactivating the non-functional human urate oxidase gene fully or even moderately by simply replacing the premature stop codons is impossible. This finding confirms the idea that a number of successive loss-of-function missense mutations occurred during evolution, making higher primates functional uricase-deficit and vulnerable to hyperuricemic disorders.
Keywords: Expression, hominoid evolution, Pichia pastoris, pseudogene, urate oxidase, uricase.
Current Pharmaceutical Biotechnology
Title:Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme
Volume: 17 Issue: 2
Author(s): Fatemeh Dabbagh, Mohammad B. Ghoshoon, Shiva Hemmati, Mozhdeh Zamani, Milad Mohkam and Younes Ghasemi
Affiliation:
Keywords: Expression, hominoid evolution, Pichia pastoris, pseudogene, urate oxidase, uricase.
Abstract: Urate oxidase is considered as an important therapeutic enzyme used to control hyperuricemia. In spite of widespread distribution in numerous (micro)organisms, active urate oxidase is absent in higher primates (humans and apes) due to gene mutations. Considering the therapeutic significance of urate oxidase, further understanding on the inactivation process of the enzyme during primate evolution is critical. This study, therefore, aims to express genetically modified human urate oxidase in the methylotrophic yeast Pichia pastoris. Accordingly, the genetically modified human urate oxidase was successfully expressed intracellularly and extracellularly under the control of an alcohol oxidase promoter and was subjected to the enzyme activity assay. The results demonstrated that reactivating the non-functional human urate oxidase gene fully or even moderately by simply replacing the premature stop codons is impossible. This finding confirms the idea that a number of successive loss-of-function missense mutations occurred during evolution, making higher primates functional uricase-deficit and vulnerable to hyperuricemic disorders.
Export Options
About this article
Cite this article as:
Dabbagh Fatemeh, Ghoshoon B. Mohammad, Hemmati Shiva, Zamani Mozhdeh, Mohkam Milad and Ghasemi Younes, Engineering Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme, Current Pharmaceutical Biotechnology 2016; 17 (2) . https://dx.doi.org/10.2174/1389201016666150907113055
DOI https://dx.doi.org/10.2174/1389201016666150907113055 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Determination of Three Tyrosine Kinase Inhibitors and One Active Metabolite by an Identical and Validated Ultra-performance Liquid Chromatography-DAD Method in Human Plasma
Current Pharmaceutical Analysis Use of Lactobacilli and their Pheromone-Based Regulatory Mechanism in Gene Expression and Drug Delivery
Current Pharmaceutical Biotechnology Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science The Quality of Life and Professional Future among Tunisian Workers Suffering from Occupational Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot-Topic: Optimizing a Therapeutic With Anti-Inflammatory Agents:Novel Drug Delivery Systems (Guest Editor: Carla Martins Lopes)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neuropeptide FF Inhibits LPS-Mediated Osteoclast Differentiation of RAW264.7 Cells
Protein & Peptide Letters Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches
Current Pharmaceutical Design Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanotechnology Platforms in Diagnosis and Treatment of Primary Brain Tumors
Recent Patents on Nanotechnology The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design
Current Pharmaceutical Design Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Cytotoxic Effects of Glass Ionomer Cements on Human Dental Pulp Stem Cells Correlate with Fluoride Release
Medicinal Chemistry Targeting Tumorangiogenesis in Lung Cancer by Suppression of VEGF and its Receptor - Results from Clinical Trials and Novel Experimental Approaches
Current Medicinal Chemistry Extra Virgin Olive Oil and Cardiovascular Diseases: Benefits for Human Health
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Chemistry of the Genus Dorstenia
Current Organic Chemistry Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) Patents in Oxidative Stress in Preeclampsia
Recent Patents on Biomarkers